Core Viewpoint - The company, International Medicine (000516.SZ), has announced that there have been no significant changes in its fundamentals, focusing on health care services and the application of modern medical technology [1] Group 1: Company Overview - The company primarily provides high-level comprehensive medical services through its affiliated medical institutions [1] - The company is not involved in the research, production, or sales of brain-computer interface products [1] Group 2: Market Context - The application of brain-computer interfaces in the medical field is currently transitioning from laboratory settings to clinical applications [1] - Revenue from rehabilitation training systems and surgeries related to brain-computer interfaces constitutes a very small portion of the company's total revenue, having minimal impact on overall performance [1]

Core Viewpoint - The company has announced that there have been no significant changes in its fundamentals, focusing on health care services and the application of modern medical technologies [1] Group 1: Company Operations - The company primarily engages in providing high-level comprehensive medical services through its affiliated medical institutions [1] - The company does not involve itself in the research, production, or sales of brain-computer interface products [1] Group 2: Market Impact - The application of brain-computer interfaces in the medical field is currently transitioning from laboratory to clinical applications [1] - Revenue generated from rehabilitation training systems and surgeries related to brain-computer interfaces constitutes a very small proportion of the company's total revenue, having minimal impact on overall performance [1] Group 3: Investor Advisory - Investors are advised to be aware of the trading risks associated with the company's stock in the secondary market and to make rational decisions [1]

Core Viewpoint - International Medical (000516.SZ) clarifies that it is not involved in the research, production, or sales of brain-computer interface products, and the revenue from related applications is minimal [1] Group 1: Company Overview - The company focuses on health care services and the application of modern medical technology [1] - Its medical institutions primarily provide high-level comprehensive medical services to patients [1] Group 2: Brain-Computer Interface Involvement - Currently, the company does not engage in the development or commercialization of brain-computer interface products [1] - The application of brain-computer interfaces in the medical field is transitioning from laboratory to clinical use [1] - Revenue from rehabilitation training systems and surgeries related to brain-computer interfaces constitutes a very small portion of the company's total revenue, having negligible impact on overall performance [1]

Core Viewpoint - The company announced that its stock price has deviated significantly, with a cumulative increase of over 20% in the last three trading days, indicating unusual trading activity [1] Company Overview - The company primarily focuses on health care services and the application of modern medical technology [1] - Its medical institutions provide high-level comprehensive medical services to patients [1] Business Operations - The company does not engage in the research, production, or sales of brain-computer interface products [1] - The application of brain-computer interfaces in the medical field is currently transitioning from laboratory to clinical use [1] - Revenue from rehabilitation training systems and surgeries related to brain-computer interfaces constitutes a very small portion of the company's total revenue, having minimal impact on overall performance [1] Investor Advisory - Investors are advised to be cautious of trading risks in the secondary market and to make rational investment decisions [1]

证券代码：000516 证券简称：国际医学 公告编号：2026-003 西安国际医学投资股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 三、是否存在应披露而未披露信息的说明 二、公司关注、核实情况 针对公司股票异常波动，公司对有关事项进行了必要的核查，现 对有关情况说明如下： 1. 公司未发现近期公共传媒报道了可能或已经对本公司股票交 易价格产生较大影响的未公开重大信息。 2. 公司目前经营情况正常，内外部经营环境未发生重大变化。 3. 公司及控股股东、实际控制人不存在应披露而未披露的重大事 项，也不存在除已披露事项外处于筹划阶段的重大事项。 4. 公司控股股东及实际控制人在本公司股票交易异常波动期间 未买卖本公司股票。 1 本公司董事会确认，本公司目前没有任何根据《深圳证券交易所 股票上市规则》等有关规定应予以披露而未披露的事项或与该事项有 关的筹划、商谈、意向、协议等；董事会也未获悉本公司有根据《深 圳证券交易所股票上市规则》等有关规定应予以披露而未披露的、对 本公司股票交易价格产生较大影 ...

Group 1 - The core point of the news is that International Medicine (000516) has seen significant share pledges from its major shareholders, indicating potential liquidity issues [1] - Shareholder Shaanxi Century Xinyuan Commercial Management Co., Ltd. has pledged a total of 75 million shares, accounting for 3.35% of the total share capital [1] - As of the announcement date, Shaanxi Century Xinyuan has pledged a total of 506 million shares, which is 82.07% of its total holdings, while shareholder Shenhua Holdings Group Co., Ltd. has pledged 45.31 million shares, representing 74.91% of its holdings [1] Group 2 - International Medicine reported a revenue of 2.995 billion yuan for the first three quarters of 2025, a year-on-year decrease of 16.94% [1] - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year, and the net profit after deducting non-recurring gains and losses was -312 million yuan, a decline of 41.94% [1] - In Q3 2025, the company recorded a single-quarter revenue of 961 million yuan, a decrease of 18.95% year-on-year, with a net profit of -129 million yuan, reflecting a significant drop of 234.24% [1] - The company's debt ratio stands at 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan, resulting in a gross profit margin of 6.59% [1] Group 3 - The main business of International Medicine includes health care services and the application of modern medical technology [2]

证券代码：000516 证券简称：国际医学 公告编号：2026-002 西安国际医学投资股份有限公司 关于控股股东进行股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"公司"）近日接到控 股股东陕西世纪新元商业管理有限公司（以下简称"世纪新元"）的通 知，2026年1月13日，世纪新元将其持有的本公司无限售条件流通股 7,500万股股票与长安国际信托股份有限公司进行了融资类质押，具体 事项如下： 二、控股股东及其一致行动人股份累计质押的基本情况 截至公告披露日，世纪新元及其一致行动人所持质押股份情况如下： | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次质 | 本次质 | 占其 | 占公 | 情况 | | 情况 | | | | | | 押前质 | 押后质 | | | | | | | | 股东 | 持股数量 | 持股 | | | 所 ...

每经AI快讯，有投资者在投资者互动平台提问：请问国际医学是否通过平阳融泰高德股权投资合伙企 业（有限合伙）持有蓝箭航天的股份？ （记者 王晓波） 国际医学（000516.SZ）1月14日在投资者互动平台表示，公司持有平阳融泰高德股权投资合伙企业 17.5439%的股权，平阳融泰高德股权投资合伙企业持有蓝箭航天0.6889%的股份。 ...

国际医学回复：您好，感谢您对公司的关注。公司旗下医疗机构依托先进的诊疗设备、技术优势和患者 资源，在脑机接口领域开展了相关课题研究，已积累一定病例样本，进行部分数据分析、文章撰写与学 术会议交流。谢谢！ 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，国际医学(000516)01月13日在投资者关系平台上答复投资者关心的问题。 投资者提问：9月11日董秘在互动平台上曾回复说：公司旗下医疗机构引进脑机接口结合外骨骼机器人 或功能性电刺激等相关康复设备的康复训练系统，开展了脑深部电刺激手术、嵴髓神经电刺激手术、迷 走神经电刺激手术等相关手术，并与相关院校及科研单位开展了脑机接口方面的研究。请问：请详细介 绍脑机接口方面的研究和临床实验。谢谢 ...

据交易所数据显示， 国际医学8天4板，今日于9时41分封涨停，成交额12.49亿元，换手率9.41%。金融 界App AI线索挖掘：近期 医疗服务板块表现活跃，国际医学被确立为国际医疗旅游试点示范基地，充 分利用自身资源平台对接海外合作伙伴，加强与 一带一路沿线国家在国际医疗旅游服务业务等医疗卫 生领域的交流合作；公司也对包括 脑机接口在内的现代前沿医学技术保持高度关注，本次非公开发行 募集资金拟用于智慧康养项目、质子治疗中心二期项目及补充流动资金，相关业务布局受到市场关注。 风险提示：连板股波动剧烈，注意追高风险，理性投资！（注：以上由AI基于交易所等公开数据生 成，内容不构成投资建议。） ...